吉利德科学(GILD)
搜索文档
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research· 2024-04-16 22:01
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this HIV and hepatitis C drugmaker have returned -7.5% over the past month versus the Zacks S&P 500 composite's -0.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 7.5% over this period. Now the key question is: Where could the stock be headed in the ...
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
Zacks Investment Research· 2024-04-10 07:21
Gilead Sciences (GILD) closed the most recent trading day at $69.94, moving +0.75% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.15%. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.32%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 7.83% over the past month. This has lagged the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65% in that time.Investors will be eagerly watc ...
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
InvestorPlace· 2024-04-10 02:40
With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential. While exercising caution is prudent, given valid underperformance reasons exist, comparing current metrics to historical peaks could reveal bargain stocks at 52-week lows. Understanding the drivers of underperformance provides insight into rebound likelihood.Since recovery duration may mirror price declines giv ...
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research· 2024-04-03 22:00
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this HIV and hepatitis C drugmaker have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 3.2% over this period. Now the key question is: Where could the stock be ...
My April Dividend Stock Buys With Yields Up To 12%
Seeking Alpha· 2024-04-02 14:17
MicroStockHub April is the start of a new month and more importantly a new quarter. Every quarter I like to review strategy and performance in my portfolio and I also like to research and find new stocks to buy that could drive portfolio gains for the rest of the year. It is getting tough to find stocks that offer value right now (and are worth buying) because the market has experienced solid gains over the past couple of months and it now trades at or near record highs. However, I have found some really in ...
Gilead Sciences Finally Starts Succeeding
Seeking Alpha· 2024-03-21 16:43
主要业务 - 吉利德科学公司的主要业务包括HIV和肿瘤药物,其中HIV产品销售额占据了公司销售额的相当大比例[4],[7] 肿瘤领域增长 - 公司在肿瘤领域取得了显著增长,肿瘤产品销售额同比增长37%,达到近30亿美元,占据了公司业务的双位数比例[4],[5] 新业务发展 - 吉利德科学公司在新业务领域也有所发展,计划2030年销售额的三分之一来自肿瘤业务,目前已有4项临床试验和近30亿美元的销售额[9],[10]
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks Investment Research· 2024-03-20 22:05
公司表现 - Gilead Sciences (GILD) 最近成为 Zacks.com 最受关注股票之一[1] - Gilead Sciences 的股价在过去一个月中上涨了 +1.9%,而 Zacks S&P 500 综合指数上涨了 +3.6%。Gilead 属于 Zacks 医疗 - 生物医学和遗传学行业,该行业在此期间下跌了 0.7%[2] - Gilead 预计本季度每股盈利为 $1.56,同比增长 +13.9%。当前财年的共识盈利预期为 $7.07,同比增长 +5.2%[5] - 下一个财年的共识盈利预期为 $7.50,同比增长 +6%[6] - Gilead 的股票评级为 Zacks Rank 3 (Hold),这是基于盈利预期变化等因素的综合评级[7] 财务表现 - 公司的营收增长预测对于评估其财务健康至关重要[8] - Gilead 当前季度的共识销售预期为 $6.3 亿,同比下降 -0.8%。当前和下一个财年的销售预期分别为 $27.45 亿和 $28.13 亿,同比增长分别为 +1.2% 和 +2.5%[9] - Gilead 上一季度的营收为 $7.12 亿,同比下降 -3.7%。每股盈利为 $1.72,与去年同期的 $1.67 相比略有增长[10] - 与 Zacks 共识预期的 $7.08 亿相比,Gilead 的营收出现了 +0.51% 的惊喜。每股盈利的惊喜为 -2.27%[11] - 在过去四个季度中,Gilead 仅一次超过了每股盈利预期,但在这段时间内三次超过了共识营收预期[12] 估值评级 - 股票的估值对于投资决策至关重要,Zacks Value Style Score 给出了 Gilead 的 A 级评级,表明其相对同行公司交易时存在折价[16] 综合展望 - 总结来看,Gilead 的股票可能会在近期与整体市场表现一致[17]
Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know
Zacks Investment Research· 2024-03-20 07:05
Gilead Sciences (GILD) closed the latest trading day at $73.41, indicating a +0.2% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.57%. Meanwhile, the Dow gained 0.83%, and the Nasdaq, a tech-heavy index, added 0.39%.Heading into today, shares of the HIV and hepatitis C drugmaker had gained 2.35% over the past month, outpacing the Medical sector's gain of 0.13% and lagging the S&P 500's gain of 2.97% in that time.Market participants will be closely foll ...
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
Businesswire· 2024-03-19 07:29
LAFAYETTE, Colo.--(BUSINESS WIRE)--The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the United States back to care. The program is funded by an eight-million-dollar grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. In this first round, CDA Foundation distributed a total of 2.1 million dollars to the following 14 grantees: Organizat ...
Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript)
2024-03-14 03:52
业绩总结 - Gilead预计到本年代末将实现加速增长[3] - Gilead拥有全球最大的HIV业务,未来将推出多款产品以推动额外增长[3] - Gilead拥有全球领先的细胞疗法业务,正在收购一家肝病公司,预计推出名为seladelpar的药物,以及在肝癌领域的产品Trodelvy[4] 未来展望 - Gilead的HIV领域未来增长重点在于一次性药物、预防性药物和广谱中和抗体[6] - Gilead计划在2023年底之前推出每6个月一次注射的预防性药物,预计将大幅扩大预防市场[17] - Gilead认为预防市场不仅适用于男同性恋和静脉注射药物使用者,还适用于所有有多个性伴侣或患有性传播疾病的人[21] 新产品和新技术研发 - Gilead计划在2023年底之前推出每6个月一次注射的预防性药物,预计将大幅扩大预防市场[17] - 针对Anito-Cel的数据表现令人鼓舞,具有较高的疗效和安全性[45] - Anito-Cel的构造与其他细胞疗法不同,具有更高的转导效率[46] 市场扩张和并购 - Gilead拥有全球领先的细胞疗法业务,正在收购一家肝病公司,预计推出名为seladelpar的药物,以及在肝癌领域的产品Trodelvy[4] - Gilead的细胞疗法业务在美国市场面临一些挑战,但预计在下半年将实现强劲增长,全球市场仍然表现强劲[35] - 公司计划在自身或外部合作伙伴的支持下,持续关注细胞疗法领域的发展[52]